法莫替丁与泮托拉唑治疗小儿消化性溃疡的临床疗效和经济效益学比较

目的 比较法莫替丁与泮托拉唑治疗小儿消化性溃疡的临床疗效和经济效益。方法 选取2011年5月—2014年2月延安大学附属医院收治的消化性溃疡患儿172例，随机分为治疗组（97例）和对照组（75例），治疗组在基础治疗上口服法莫替丁片，1片/次，2次/d。对照组则口服泮托拉唑胶囊，2粒/次，1次/d。两组均持续治疗1个月。观察2组的临床疗效，并运用成本–效果分析法进行药物经济学评价。结果 治疗组和对照组临床愈显率分别为68.04%、76.00%，两组比较差异无统计学意义；总有效率分别为91.74%、94.67%，两组比较差异无统计学意义。治疗组成本–效果比显著低于对照组，两组比较差异有统计学意义（P<0.01）。治疗组总治疗花费明显低于对照组，两组比较差异具有统计学意义（P<0.05）。结论 法莫替丁治疗小儿消化性溃疡有较好的临床疗效，且治疗花费明显低于泮托拉唑，经济学价值更加明显，更加适合基层医院使用。

Clinical efficacy and pharmacoeconomic analysis of famotidine and pantoprazole in treatment of pediatric peptic ulcer

Objective To compare the clinical efficacy and pharmacoeconomic analysis of famotidine and pantoprazole in the treatment of pediatric peptic ulcer. Methods Pediatric peptic ulcer patients (172 cases) in Affiliated Hospital of Yanan University from May 2011 to February 2014 were randomly divided into treatment (97 cases) and control (75 cases) groups. Patients in the treatment group were po administered with Famotidine Tablets, 1 tablet/time, twice daily. Patients in the control group were po administered with Pantoprazole Capsules, 2 grains/time, once daily. All the patients were treated continuously for 1 month. The total clinical efficacy was observed, and pharmacoeconomics was evaluated by the cost-effectiveness method.Results The markedly effective rates in the treatment and control groups were 68.04% and 76.00%, respectively, with no significant difference between the two groups. The efficacies in the treatment and control groups were 91.74% and 94.67%, respectively, and there were no differences between the two groups. The cost-effectiveness of the treatment group was lower than that of the control group, and there were differences between the two groups (P < 0.01). The total treatment cost of treatment group was significantly lower than that in the control group, and there were differences between the two groups (P < 0.05). Conclusion Famotidine has good curative effect in treatment of pediatric peptic ulcer, and the treatment cost is significantly lower than the pantoprazole with more obvious economic value, which is more suitable for primary hospitals.